Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study
Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study
Article first published online: 5 JUL 2002
Acta Psychiatrica Scandinavica
Volume 106, Issue 1, pages 20–26, July 2002
How to Cite
Starace, F. , Bartoli, L. , Aloisi, M. S. , Antinori, A. , Narciso, P. , Ippolito, G. , Ravasio, L. , Moioli, M. C. , Vangi, D. , Gennero, L. , Coronado, O. V. , Giacometti, A. , Nappa, S. , Perulli, M. L. , Montesarchio, V. , La Gala, A. , Ricci, F. , Cristiano, L. , De Marco, M. , Izzo, C. , Pezzotti, P. , D'Arminio Monforte, A. and for the NeuroICONA study team (2002), Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study . Acta Psychiatrica Scandinavica, 106: 20–26. doi: 10.1034/j.1600-0447.2002.02289.x
- Issue published online: 5 JUL 2002
- Article first published online: 5 JUL 2002
- HIV infections;
- neuropsychological test;
- cognitive disorder;
Objective: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors.
Method: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery.
Results: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P=0.05).
Conclusion: Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol.